Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

NCT03644589 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants enrolled.

Conditions

Estrogen Receptor Negative
HER2/Neu Negative
Metastatic Breast Cancer
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Triple Negative Breast Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Cisplatin

Sponsor

University of Washington

Collaborators

[object Object]